Payment overview · 2025
General Payments
$1,520.45
89 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher D Reyes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PINCKNEYVILLE, IL · NPI 1407828940
Verified facts
What the public records show
CMS Open Payments records show Christopher D Reyes, M.D. received $1,520.45 in general payments during 2025 across 89 reported records.
Novartis Pharmaceuticals Corporation accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $294.76 | 19.4% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $290.61 | 19.1% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $279.58 | 18.4% | 23 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $164.73 | 10.8% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.40 | 9.0% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.77 | 5.7% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.43 | 4.8% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $45.47 | 3.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.19 | 2.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.94 | 2.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.49 | 1.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.97 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.04 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.07 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,520.45 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $294.76 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $205.48 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $205.48 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $168.89 | 17 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $135.91 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.60 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $110.69 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $73.43 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $70.20 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.20 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.26 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.42 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $45.47 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.89 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.19 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $10.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 120 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 370 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 351 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 40 |
| Potassium Chloride | Potassium Chloride | 221 | 39 |
| Lorazepam | Lorazepam | 214 | 42 |
| Metformin Hcl | Metformin Hcl | 206 | 34 |
| Omeprazole | Omeprazole | 196 | 49 |
| Alprazolam | Alprazolam | 190 | 34 |
| Lisinopril | Lisinopril | 188 | 47 |
| Furosemide | Furosemide | 182 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 23 |
| Carvedilol | Carvedilol | 129 | 21 |
| Meloxicam | Meloxicam | 129 | 27 |
| Trazodone Hcl | Trazodone Hcl | 129 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 30 |
| Farxiga | Dapagliflozin Propanediol | 120 | 20 |
| Eliquis | Apixaban | 106 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 102 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 21 |
| Spironolactone | Spironolactone | 101 | 24 |
| Pregabalin | Pregabalin | 98 | 22 |
| Montelukast Sodium | Montelukast Sodium | 92 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 15 |
| Famotidine | Famotidine | 88 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 19 |
| Tramadol Hcl | Tramadol Hcl | 84 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 80 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 20 |
| Warfarin Sodium | Warfarin Sodium | 79 | suppressed |
| Losartan Potassium | Losartan Potassium | 78 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 19 |
| Allopurinol | Allopurinol | 76 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 14 |
| Ozempic | Semaglutide | 74 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 23 |
| Simvastatin | Simvastatin | 73 | 16 |
| Topiramate | Topiramate | 72 | suppressed |
| Jardiance | Empagliflozin | 68 | 13 |
| Mounjaro | Tirzepatide | 68 | 11 |
| Clonazepam | Clonazepam | 67 | 20 |
| Donepezil Hcl | Donepezil Hcl | 67 | 13 |
| Mirtazapine | Mirtazapine | 67 | 17 |
| Sertraline Hcl | Sertraline Hcl | 66 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 15 |
| Prednisone | Prednisone | 61 | 42 |
| Glipizide | Glipizide | 57 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | suppressed |
| Nabumetone | Nabumetone | 53 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 52 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 51 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 11 |
| Metformin Hcl Er | Metformin Hcl | 47 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Glimepiride | Glimepiride | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 11 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Sucralfate | Sucralfate | 44 | suppressed |
| Fluconazole | Fluconazole | 43 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 30 |
| Azithromycin | Azithromycin | 37 | 29 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 13 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Colchicine | Colchicine | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 18 |
| Nystatin | Nystatin | 28 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | 11 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Risperidone | Risperidone | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Primidone | Primidone | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 19 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Methimazole | Methimazole | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 12 |
| Torsemide | Torsemide | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,520.45 · 89 records | Novartis Pharmaceuticals Corporation | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, ELIQUIS, FANAPT, FARXIGA, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, YUPELRI, ZENPEP, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error